Eszopiclone in Australia – Patient Information and Comprehensive Guide
Basic Product Information
- International Non-Proprietary Name (INN): Eszopiclone
- Common Australia Brand Name: Lunivia (not widely available as of 2024), generic preparations may be ordered at the prescriber’s discretion.
- ATC Code: N05CF04
- Available Forms and Strengths:
- Film-coated tablets: 1 mg, 2 mg, 3 mg
- Manufacturers: Limited approval in Australia; principal international manufacturers are Sun Pharma, Teva, and Glenmark. Supply under the Special Access Scheme (SAS) is typical.
- Prescription Status: Schedule 4 (Prescription-only Medicine). Authorisation and specialist prescription may be required via SAS.
Mechanism of Action
For patients: Eszopiclone is a medicine that helps you fall asleep and stay asleep. It acts by calming brain activity, making it easier to relax and drift off.
For specialists: Eszopiclone is a non-benzodiazepine hypnotic with selective agonism at the GABAA receptor complex, particularly at the omega-1 (BZ1) site. This enhances GABAergic inhibitory transmission in the CNS and promotes sleep without significant alteration of sleep architecture in therapeutic doses.
Pharmacokinetics
- Absorption: Rapidly absorbed after oral administration; peak plasma concentration reached within 1 hour (median Tmax).
- Metabolism: Extensively metabolised in the liver via CYP3A4 and CYP2E1 isoenzymes to inactive metabolites.
- Elimination: Primarily through renal excretion as metabolites.
- Duration of action: Elimination half-life is approximately 6 hours. Residual clinical effect may extend up to 8 hours in sensitive populations (elderly, reduced hepatic function).
Use in Everyday Life and Best Practices
Eszopiclone is typically prescribed for the short-term management of adults with difficulty falling asleep, staying asleep, or waking too early (insomnia). In Australia, careful assessment and identification of underlying causes of sleep disturbance are recommended before issuing a prescription.
- Typical adult dose: 2 mg or 3 mg taken immediately before bedtime, as needed. The lowest effective dose should be used.
- How to take: Swallow whole with water. Do not crush or chew tablets.
- Length of use: Treatment is usually limited to 2–4 weeks. Prolonged use may require specialist review.
Good sleep hygiene—such as maintaining a regular bedtime and reducing stimulants like coffee and tea—should be practised alongside medication use, as advised by Australian clinical guidelines.
Dosing in the Morning vs Evening
- Evening (Recommended): Eszopiclone must be taken just before going to bed. Taking it at night maximises sleep-inducing effects and reduces the risk of morning drowsiness.
- Morning: Not advised. May cause significant daytime sleepiness, impaired alertness, and increased risk of accidents (driving, workplace hazards).
- Tips for regular use: Take at the same time each night when you are able to get a full night's sleep (7–8 hours).
Taking with Food or on an Empty Stomach
- Taking Eszopiclone on an empty stomach helps it work faster for falling asleep.
- If taken after a heavy meal (e.g., a typical English dinner with meat and potatoes), it may take longer for the effect to begin.
- Tip: Avoid fatty, late-night snacks around the time of dosing if rapid onset is desired, in keeping with Australian dietary habits.
Interaction Warnings
| Interaction | Effect/Recommendation |
|---|---|
| Alcohol | Increases sedation and risk of overdose. Do not use together. |
| CYP3A4 Inhibitors (e.g., ketoconazole, erythromycin) | May increase Eszopiclone levels and effects. Monitor and use lower doses if needed. |
| Other Sedatives (benzodiazepines, opioids, antihistamines) | Increased risk of CNS depression and respiratory suppression. |
| Grapefruit juice | Rare, but possible increased drug levels. Prefer to avoid. |
| St John's Wort | May reduce effectiveness. Avoid combination. |
Indications
| Indication | Status in Australia | Comments |
|---|---|---|
| Primary insomnia (short-term) | Approved (SAS) | For adults struggling with sleep onset or maintenance |
| Chronic insomnia | Off-label/Specialist | Continued review and specialist oversight recommended |
| Other sleep disorders | Not approved | Alternative treatments preferred |
Dosing According to Clinical Indication
| Group | Starting Dose | Typical Maintenance Dose | Maximum Dose |
|---|---|---|---|
| Adults (18–64 yrs) | 1 mg before bed | 2–3 mg before bed | 3 mg per night |
| Elderly (≥65 yrs) | 1 mg before bed | 2 mg before bed (if tolerated) | 2 mg per night |
| Paediatric (<18 yrs) | Not recommended | — | — |
| Hepatic impairment | 1 mg before bed | Adjust under medical supervision | 2 mg per night |
Safety Profile and Side Effects
| Common Side Effects | Rare Side Effects | Warnings |
|---|---|---|
|
|
|
Guidelines for Proper Use
- Use the lowest effective dose for the shortest period possible.
- Avoid alcohol, recreational sedatives, or strong painkillers during treatment.
- Maintain a regular sleep schedule—get up and go to bed at the same times, even on weekends.
- Discuss any history of mental health conditions, substance misuse, or lung/liver disease with your pharmacist or doctor first.
- If daytime drowsiness occurs, reduce dose or consult your prescriber.
- Report any memory changes or unusual night-time behaviours promptly.
- Do not share your medication with others or keep unused tablets ‘just in case’.
- Store securely, away from children and pets.
Alternative Treatment Options
- Zopiclone (Imovane): Widely prescribed in Australia, similar mechanism and effect, broader access on the PBS for qualifying patients.
- Temazepam (Normison, Temaze): Benzodiazepine hypnotic, government reimbursed, but with increased risk of dependence for long-term use.
- Melatonin MR (Circadin): Approved for adults aged 55+, PBS subsidised for primary insomnia in certain cases. Mildest side effect profile.
- Doxylamine or promethazine: Older antihistamine-class sedatives; available OTC for short-term use, but more likely to cause daytime sedation and anticholinergic side effects.
- Cognitive Behavioural Therapy for Insomnia (CBT-I): Australian guidelines recommend CBT-I as a first-line, non-drug therapy for chronic insomnia.
| Alternative | Pros | Cons |
|---|---|---|
| Zopiclone | Similar efficacy; wider PBS coverage | Similar side effects; possible taste disturbance |
| Temazepam | Effective, familiar to clinicians | Risk of habit, withdrawal; restrictive regulation |
| Melatonin MR | Safe, non-addictive, minimal next-day effects | Lower potency; age-restricted PBS listing |
| CBT-I | Non-drug, first-line for chronic insomnia | Requires time, commitment, clinician availability |
Legal, Registration, and Reimbursement Status in Australia
- Regulatory body: Therapeutic Goods Administration (TGA)
- Current registration: Eszopiclone is approved for use via the Special Access Scheme (SAS); not available on the PBS nor listed for broad reimbursement as of 2024.
- Prescription requirements: Schedule 4 (S4: prescription-only medicine). Requires specialist initiation and TGA notification under SAS pathways.
- Professional guidelines: Prescribing should adhere to RACGP and NPS MedicineWise recommendations on hypnotic use for insomnia.
Latest Research/Clinical Guidance (2022–2025)
- Current English and international literature, including NICE Insomnia Guidelines and RACGP (2023), now discourage routine long-term use of hypnotics—including eszopiclone—due to risk of dependence and limited real-world benefit after 4 weeks.
- International meta-analyses confirm efficacy in sleep onset and duration, but recommend prioritising behavioural and psychological interventions (CBT-I) and careful patient selection for pharmacotherapy.
- Recent reviews:
- Morin CM, Drake CL. “Pharmacological management of insomnia: update and prescribing frameworks for 2024.” J Sleep Res. 2024;33(1):e14187.
- Lancet Psychiatry. “Insomnia treatments and clinical outcomes.” 2023;10(7):547–555.
Availability and Delivery
- Pack sizes: Typically 14 or 28 tablets per pack under SAS supply.
- Indicative cost (2024): $45–$85 per pack (not reimbursed).
- Availability: Only through SAS pharmacies and with specialist prescription. Not routinely stocked in local chemists; advanced order and wait times apply.
| City | Estimated Delivery Time | Pharmacy/Clinic Options |
|---|---|---|
| Sydney | 3–5 business days | Authorised SAS Clinic Dispensary |
| Melbourne | 3–7 business days | Specialist hospital pharmacy |
| Brisbane | 4–8 business days | Compounding pharmacies (with order) |
| Adelaide | 5–9 business days | SAS-registered pharmacies |
| Perth | 5–10 business days | Specialist provider network |
FAQ – Most Common Patient Questions
- Q: Is eszopiclone available from my usual pharmacy?
A: No, eszopiclone is not routinely stocked in community pharmacies. It is supplied via the Special Access Scheme (SAS) with specialist prescription and advanced order. - Q: Can I drive the morning after taking eszopiclone?
A: It is safest to wait until you feel completely alert. Residual drowsiness can impair performance; avoid driving or operating machinery for at least 8 hours after taking eszopiclone, and longer if you feel unwell. - Q: What happens if I miss a dose?
A: Do not take eszopiclone in the middle of the night or double your next dose. Resume your usual regimen at bedtime the next night. - Q: Is it safe to take eszopiclone with my usual medicines?
A: Always inform your prescriber and pharmacist of all medicines, vitamins, and supplements you take. Some drug interactions can increase risk of sedation or reduce effect. - Q: Can I become dependent on eszopiclone?
A: There is a risk of dependence with prolonged or excessive use. Always follow your doctor’s instructions for dose and duration, and discuss any concerns about stopping or tapering treatment.
This information is intended to support, not replace, advice from your doctor or pharmacist. For further guidance, consult your healthcare provider or contact the Therapeutic Goods Administration for authoritative Australian regulatory and safety updates.
